Trials / Completed
CompletedNCT00666770
A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 309 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep in subjects with transient insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabapentin | Gabapentin 250 mg oral capsule 30 minutes prior to bedtime |
| DRUG | Gabapentin | Gabapentin 500 mg oral capsule 30 minutes prior to bedtime |
| DRUG | Placebo | Matched placebo 30 minutes prior to bedtime |
Timeline
- Start date
- 2004-10-01
- Completion
- 2004-11-01
- First posted
- 2008-04-25
- Last updated
- 2021-02-02
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00666770. Inclusion in this directory is not an endorsement.